EUCTR2018-001639-35-HU进行中（未招募）1 期
Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment - PATTERN (Multi-PAttern TreaTment of uppEr and loweR limb with iNcobotulinumtoxinA)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Main inclusion criteria
- •Female or male subject = 18 years and = 85 years at screening
- •Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury
- •Disabling ankle flexor spasticity presenting as pes equinus or pes equinovarus
- •Modified Ashworth Scale-Bohannon [MAS] score of 2 or 3 points in the ankle plantar flexor of the target lower limb (supine position, knee extended)
- •Minimum passive range of motion in ankle of the target lower limb (supine position, knee extended): 10°dorsiflexion and 20°plantarflexion
- •At least 4 months since last botulinum neurotoxin [BoNT] injection for treatment of spasticity or any other condition
- •For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an:
- •o Activated partial thromboplastin time [aPTT] = 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or
- •o International normalized ratio [INR] value of = 2.5 (subjects on coumarins or other anticoagulants monitored by INR)
- •Main eligibility criteria for re-injection
- •According to the experience-based opinion of the investigator, the subject must have a clinical need for 400 U of NT 201 in the affected lower limb
- •Body weight at least 50 kg
- •Negative urine pregnancy test for women of childbearing potential
- •For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an:
- •o aPTT = 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or
- •o INR value of = 2.5 (subjects on coumarins or other anticoagulants monitored by INR)
- •No infection or inflammation in the area of the planned injection sites at the visits
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 450
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •Main exclusion criteria
- •Generalized disorders of muscle activity (e.g. myasthenia gravis, Lambert Eaton syndrome, amyotrophic lateral sclerosis) or any other significant peripheral neuromuscular dysfunction which might interfere with the study
- •Bilateral lower limb paresis/paralysis/spasticity or tetraparesis/paralysis/spasticity
- •Body weight < 50 kg
- •Severe atrophy of the target limb muscles
- •Previous, ongoing or planned treatments of spasticity with intrathecal baclofen
- •Previous, ongoing, or planned treatments of spasticity in the target lower limb with any of the following procedures:
- •o Surgical intervention
- •o Alcohol or phenol block
- •o Muscle afferent block
- •Physiotherapy or use of orthoses or splints at the target limb initiated less than 4 weeks before screening or expected to change during the double blind phase of the study
- •Current or planned treatment with parenterally administered drugs that interfere with neuromuscular transmission (e.g. intrathecal baclofen, tubocurarine type muscle relaxants used in anesthesia),, or local anesthetics in the treated region within 2 weeks prior to screening
- •Infection or inflammation at the injection sites
- •Subjects with presence or history of aspiration pneumonia, recurrent lower respiratory tract infections, or compromised respiratory function as per investigator's clinical judgment
- •Pregnancy (as verified by a positive pregnancy test) or breast feeding
研究者
相似试验
招募中
4 期
Prospective, randomized, double-blind, placebo-controlled, multicenter clinical investigation to determine the clinical performance and safety of Luvos® Healing Earth in patients with histamine-mediated recurrent digestive symptoms.T78.1T62K58K59Other adverse food reactions, not elsewhere classifiedToxic effect of other noxious substances eaten as foodOther functional intestinal disordersIrritable bowel syndromeDRKS00027333Heilerde-Gesellschaft Luvos Just GmbH % Co. KG114
进行中（未招募）
不适用
Dose finding study for a Botulinum toxin type A injection to treat habitual snoringEUCTR2011-001779-38-DEMerz Pharmaceuticals GmbH48
进行中（未招募）
1 期
Cineole in acute non-purulent rhinosinusitisEUCTR2016-002743-41-DEEngelhard Arzneimittel GmbH & Co. KG250
进行中（未招募）
不适用
Prospective clinical trial, in which the test product (a cream containing 2% of Sertaconazol a known anti-mycotic ingredient) or the comparator product (cream without any active ingredient) are being dispatched randomly to the patients without that they or their physicians know which product they receive. Objective is to explore the anti-itch potential of the test product in atopic dermatitis as well as its safety and its local tolerability.Atopic DermatitisEUCTR2012-003954-95-DESpirig Pharma AG
进行中（未招募）
不适用
Clinical study to investigate the efficacy and safety of NT 201 compared to placebo in the treatment of chronic troublesome drooling associated with neurological disorders and/or intellectual disabilityChronic troublesome sialorrhea associated with neurological disorders (e.g. cerebral palsy, traumatic brain injury) and/or intellectual disability in children and adolescentsMedDRA version: 18.0Level: PTClassification code 10039424Term: Salivary hypersecretionSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2013-004532-30-Outside-EU/EEAMerz Pharmaceuticals GmbH249